FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Patent & Trademark Office (PTO) has completed the first of four reexamination proceedings and has confirmed the patentability of U.S. Patent No. 6,043,230, which covers a method of use for Viread (tenofovir disoproxil fumarate). The U.S. PTO has not announced its ruling on the remaining three Viread patents under review.
